Payment overview · 2025
General Payments
$2,944.58
265 reported records · 27 companies
Healthcare provider profile · identity verified
Mark A Leiker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WICHITA, KS · NPI 1881698348
Verified facts
What the public records show
CMS Open Payments records show Mark A Leiker, M.D. received $2,944.58 in general payments during 2025 across 265 reported records.
PFIZER INC. accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 53 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $384.67 | 13.1% | 56 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $335.44 | 11.4% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $303.92 | 10.3% | 58 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $267.31 | 9.1% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $220.54 | 7.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $218.23 | 7.4% | 23 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $158.94 | 5.4% | 23 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.57 | 5.4% | 15 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $142.47 | 4.8% | 13 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $96.45 | 3.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $90.18 | 3.1% | 5 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $84.40 | 2.9% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $76.18 | 2.6% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$59.64 | 2.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $56.01 | 1.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.27 | 1.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.62 | 1.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.57 | 1.2% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $30.83 | 1.1% | 2 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $26.20 | 0.9% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.54 | 0.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.28 | 0.6% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $15.56 | 0.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $15.53 | 0.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.23 | 0.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.14 | 0.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.86 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,944.58 | 265 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $335.44 | 16 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $311.80 | 48 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $194.57 | 18 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $192.05 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $181.31 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $172.81 | 35 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $163.15 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $152.82 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $143.91 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $142.47 | 13 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $139.46 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $139.25 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.15 | 32 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $115.71 | 19 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $96.45 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $90.18 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $84.86 | 14 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $84.40 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $83.06 | 12 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $76.18 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.08 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $74.08 | 9 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $72.40 | 7 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $72.40 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $72.40 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.02 | 5 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $59.64 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $59.56 | 9 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $56.01 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.62 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $42.46 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.67 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $26.99 | 3 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $26.20 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.46 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $10.67 | 2 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $4.56 | 1 | 2025 |
Source payment records
|
|||||
| LILETTA Normalized: liletta |
Drug | ABBVIE INC. | $2.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 112 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 26 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
26 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 477 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 378 | 84 |
| Lisinopril | Lisinopril | 375 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 283 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 274 | 77 |
| Simvastatin | Simvastatin | 272 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 271 | 76 |
| Metformin Hcl Er | Metformin Hcl | 260 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 235 | 73 |
| Losartan Potassium | Losartan Potassium | 224 | 61 |
| Sertraline Hcl | Sertraline Hcl | 184 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 51 |
| Gabapentin | Gabapentin | 169 | 39 |
| Omeprazole | Omeprazole | 165 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 27 |
| Allopurinol | Allopurinol | 147 | 37 |
| Meloxicam | Meloxicam | 123 | 40 |
| Metformin Hcl | Metformin Hcl | 123 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 119 | 34 |
| Finasteride | Finasteride | 116 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 37 |
| Eliquis | Apixaban | 112 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 105 | 61 |
| Alendronate Sodium | Alendronate Sodium | 104 | 26 |
| Tramadol Hcl | Tramadol Hcl | 103 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 24 |
| Farxiga | Dapagliflozin Propanediol | 99 | 21 |
| Trazodone Hcl | Trazodone Hcl | 98 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 27 |
| Furosemide | Furosemide | 92 | 32 |
| Potassium Chloride | Potassium Chloride | 91 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 24 |
| Prednisone | Prednisone | 82 | 68 |
| Montelukast Sodium | Montelukast Sodium | 79 | 25 |
| Clonazepam | Clonazepam | 75 | 19 |
| Glimepiride | Glimepiride | 75 | 17 |
| Warfarin Sodium | Warfarin Sodium | 75 | 12 |
| Carvedilol | Carvedilol | 74 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 18 |
| Mounjaro | Tirzepatide | 67 | suppressed |
| Alprazolam | Alprazolam | 66 | 14 |
| Atenolol | Atenolol | 66 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 17 |
| Ozempic | Semaglutide | 63 | 12 |
| Jardiance | Empagliflozin | 62 | 11 |
| Lovastatin | Lovastatin | 61 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 15 |
| Januvia | Sitagliptin Phosphate | 54 | 12 |
| Ezetimibe | Ezetimibe | 52 | 16 |
| Bupropion Xl | Bupropion Hcl | 51 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 16 |
| Telmisartan | Telmisartan | 49 | 13 |
| Terazosin Hcl | Terazosin Hcl | 48 | 13 |
| Lorazepam | Lorazepam | 46 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 35 |
| Estradiol | Estradiol | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 12 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 22 |
| Mupirocin | Mupirocin | 33 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 24 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 14 |
| Valsartan | Valsartan | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 13 |
| Famotidine | Famotidine | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 18 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 17 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 11 |
| Dexamethasone | Dexamethasone | 21 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 12 |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,944.58 · 265 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, COMIRNATY, CREON, Dexcom G6 Transmitter, Doc Band, ELIQUIS, EMGALITY, ENTRESTO, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, INTELLIS ADAPTIVESTIM, JARDIANCE, JASCAYD, KISUNLA, Kerendia, Korlym, LEQVIO, LILETTA, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OFEV, OTEZLA, Omnipod, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, Senza, TRELEGY ELLIPTA, Tymlos, UBRELVY, VRAYLAR, Wegovy, XHANCE, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error